Longer Duration of Treatment with ICIs Associated with a Higher Rate of Complete Response Among Patients with MMRd Cancers By Ogkologos - March 5, 2025 508 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a systematic review of published studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma Ahead of ESMO Immuno-Oncology Congress 2025: topics at a glance MOST POPULAR What to Know About Peer-Reviewed Cancer Information and Its Role in... August 10, 2022 Trial Results Support Adding Daratumumab to Initial Treatment for Multiple Myeloma January 19, 2024 Restaurant Opens Early For A 3-Year-Old Girl With Leukemia So She... February 21, 2020 The award-winning team transforming breast cancer treatment April 10, 2022 Load more HOT NEWS Sisters on Opposite Sides of the Country Diagnosed with Breast Cancer... This Breast Cancer Patient Is Using Boudoir Photography to Reclaim Her... Shortening Duration of Adjuvant Treatment from 6 to 3 Months Did... For Cancer Screening, COVID-19 Pandemic Creates Obstacles, Opportunities
